MedTrace Logo

BAY59-7939 in Atrial Fibrillation Once Daily (OD)

NCT00973245 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2014-12-30

No results posted yet for this study

Summary

This is an exploratory investigation of safety, pharmacokinetic (PK) and pharmacodynamic (PD) effects of BAY59-7939 with multiple oral doses of 10 mg, 15 mg and 20 mg once daily (od) in Japanese subjects with non-valvular atrial fibrillation (originally described in Japanese).

Conditions

Interventions

DRUG

Xarelto (Rivaroxaban, BAY59-7939)

10mg od

DRUG

Xarelto (Rivaroxaban, BAY59-7939)

15mg od

DRUG

Xarelto (Rivaroxaban, BAY59-7939)

20mg od

DRUG

Warfarin

Dose-adjusted warfarin based on target INR values

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Completion
2007-01-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00973245 on ClinicalTrials.gov